Screener
Dianthus Therapeutics DNTH Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 34,528 | 27,003 |
| General and administrative | 12,468 | 7,337 |
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): | ||
| Interest and investment income | 6,265 | 3,791 |
| Loss on investment in former related party | (302) | (5) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's other operating expenses?
- Dianthus Therapeutics (DNTH) reported other operating expenses of $47M in Q1 2026.
- How has Dianthus Therapeutics's other operating expenses changed year-over-year?
- Dianthus Therapeutics's other operating expenses increased by 36.9% year-over-year, from $34.34M to $47M.
- What is the long-term trend for Dianthus Therapeutics's other operating expenses?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's other operating expenses has grown at a 13.1% compound annual growth rate (CAGR), from $74.69M to $108.1M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Dianthus Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude